Table 1.
Summary of the HD phenotypes affected by 4b treatment at different doses
| Test | Sex | 100 mg/kg | 50 mg/kg | 15 mg/kg |
|---|---|---|---|---|
| Body weight | Male | NS | NS | NS |
| Female | **P < 0.001 | NS | NS | |
| Rotarod | Male | ***P < 0.0001 | ***P < 0.0001 | NS |
| Female | *P = 0.041 | *P = 0.042 | NS | |
| Brain weight | Male and female | ND | NS | ND |
| T-maze | Male and female | ND | *P < 0.05 | ND |
| Survival | Male and female | NS | NS | NS |
| Open field | ||||
| Ambulatory distance | Male and female | ND | **P = 0.004 | *P = 0.011 |
| Ambulatory time | Male and female | ND | P = 0.01 | *P = 0.017 |
| Stereotypic time | Male and female | ND | NS | *P = 0.025 |
| Mean velocity | Male and female | ND | ***P = 0.0002 | NS |
| Vertical counts | Male and female | ND | **P = 0.004 | NS |
| Vertical time | Male and female | ND | ***P = 0.0005 | NS |
All doses were administered subcutaneously. Statistical analyses for the different tests included two-way ANOVAs and Student's t-tests, as described in Materials and Methods. NS, non-significant; ND, not determined.